Based on the Coherus BioSciences Inc stock forecast from 2 analysts, the average analyst target price for Coherus BioSciences Inc is USD 6.20 over the next 12 months. Coherus BioSciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Coherus BioSciences Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Coherus BioSciences Inc’s stock price was USD 1.06. Coherus BioSciences Inc’s stock price has changed by +37.43% over the past week, +15.20% over the past month and -51.82% over the last year.
No recent analyst target price found for Coherus BioSciences Inc
No recent average analyst rating found for Coherus BioSciences Inc
Company Overview Coherus BioSciences Inc
Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. The company was incorporated in 2010 and is based in Redwood City, California. Read Less
Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel ne...Read More
Frequently Asked Questions About Coherus BioSciences Inc (CHRS) Stock
Based on ratings from 2 analysts Coherus BioSciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on CHRS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CHRS is USD 6.20 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.
CHRS stock's Price/Earning ratio is 4.12.
Our analysis grades CHRS stock's Price / Earning ratio at F. This means that CHRS stock's Price/Earning ratio is above 44.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CHRS may be fairly valued for its sector
The last closing price of CHRS's stock was USD 1.06.
The most recent market capitalization for CHRS is USD 0.12B.
Based on targets from 2 analysts, the average taret price for CHRS is projected at USD 6.20 over the next 12 months.
This means that CHRS's stock price may go up by +484.91% over the next 12 months.
We can't find any ETFs which contains Coherus BioSciences Inc's stock.
As per our most recent records Coherus BioSciences Inc has 228 Employees.
Coherus BioSciences Inc's registered address is 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065.
You can get more information about it from Coherus BioSciences Inc's website at https://www.coherus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Coherus BioSciences Inc (CHRS) Stock
Based on ratings from 2 analysts Coherus BioSciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on CHRS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CHRS is USD 6.20 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.
CHRS stock's Price/Earning ratio is 4.12.
Our analysis grades CHRS stock's Price / Earning ratio at F. This means that CHRS stock's Price/Earning ratio is above 44.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CHRS may be fairly valued for its sector
The last closing price of CHRS's stock was USD 1.06.
The most recent market capitalization for CHRS is USD 0.12B.
Based on targets from 2 analysts, the average taret price for CHRS is projected at USD 6.20 over the next 12 months.
This means that CHRS's stock price may go up by +484.91% over the next 12 months.
We can't find any ETFs which contains Coherus BioSciences Inc's stock.
As per our most recent records Coherus BioSciences Inc has 228 Employees.
Coherus BioSciences Inc's registered address is 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065.
You can get more information about it from Coherus BioSciences Inc's website at https://www.coherus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CHRS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
